BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS). BrainsWayâs flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications. BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders. BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY. Source
No articles found.
Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and mar...
Sonoma Pharmaceuticals is a specialty pharmaceu...
Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing ...
Seres Therapeutics, Inc. is a microbiome therap...
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and ...
Catalyst Pharmaceuticals is a biopharmaceutical...
Alseres Pharmaceuticals, Inc. is focused on the development of diagnostic and ther...
Alseres Pharmaceuticals, Inc. is focused on the...
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrate...
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a Sa...
SI-BONE is a medical device company that has pioneered a proprietary minimally inv...
SI-BONE is a medical device company that has pi...
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (â...
Lantheus Holdings, Inc. is the parent company o...
Join the National Investor Network and get the latest information with your interests in mind.